Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Tozinameran

Pemphigus vulgaris: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Solimani F, et al. Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2. Journal of the European Academy of Dermatology and Venereology 35: e649-e651, No. 10, Oct 2021. Available from: URL: http://doi.org/10.1111/jdv.17480 Solimani F, et al. Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2. Journal of the European Academy of Dermatology and Venereology 35: e649-e651, No. 10, Oct 2021. Available from: URL: http://​doi.​org/​10.​1111/​jdv.​17480
Metadaten
Titel
Tozinameran
Pemphigus vulgaris: case report
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-16262-y

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Tozinameran

Case report

Prednisone

Case report

Antineoplastics

Case report

Remdesivir